Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib-Reference-Cited by-同舟云学术

Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib

Published:2024-07-31 Issue:9 Volume:38 Page:2046-2050
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Leyte-Vidal Ariel,DeFilippis RosaAnna^ORCID,Outhwaite Ian R.^ORCID,Kwan Isabelle,Lee Ji Young^ORCID,Leavitt Carlyn,Miller Kaeli B.,Rea Delphine^ORCID,Rangwala Aziz M.^ORCID,Lou Kevin,Patel Suhana,Alvarez Ailin,Shokat Kevan M.,Bahar Ivet,Seeliger Markus A.^ORCID,Shah Neil P.^ORCID

Funder

American Society of Hematology

U.S. Department of Health & Human Services | National Institutes of Health

Samuel Waxman Cancer Research Foundation

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41375-024-02353-0.pdf

Reference15 articles.

1. Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, et al. Asciminib in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2024. online ahead of print.

2. Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 2017;543:733–7.

3. Hochhaus A, Rea D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023;37:617–26.

4. Eide CA, Zabriskie MS, Savage Stevens SL, Antelope O, Vellore NA, Than H, et al. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants. Cancer Cell. 2019;36:431–43.e435. online ahead of print.

5. Leyte-Vidal A, Garrido Ruiz D, DeFilippis R, Leske IB, Rea D, Phan S, et al. BCR::ABL1 Kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib. Blood. 2024.